Aurobindo Pharma signs pact with Singapore-based Hilleman Labs for children vaccine

Aurobindo Pharma Limited's wholly-owned subsidiary Auro Vaccines Private Limited on Wednesday informed that it has entered into a licence agreement with Hilleman Laboratories Singapore Pte. Limited.

 

According to the filing, the agreement is about developing, manufacturing and commercializing a pentavalent vaccine candidate used in children vaccination. 

 

Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate, the company said in a statement.

 

Shares of Aurobindo Pharma were under pressure in the morning session due to market volatility and trading at Rs876 per share lower by 0.47% on the BSE today.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

14 mins read . 06 Dec 2024

Stocks Under 1000 Rupees in India

  • 0 people read
blog-logo

Economy

blog-logo

8 mins read . 05 Dec 2024

History of Reliance Group

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions